Statins: A Distant Hope and Thousand Dangers in Near

Abstract

Atherosclerotic Cardiovascular Disease (ASCVD) is a common
cause of morbidity and mortality and can impose a high budget
to all health services. The American College of Cardiology/
American Heart Association (ACC/AHA) recommended
the initiation of high-intensity statin therapy in patients with
clinical ASCVD regardless of baseline low-density lipoprotein
cholesterol (LDL-C) levels.[1] Statin, a commonly and effective
therapy for dyslipidemia besides diet and exercise introduced
by Merck in November 1986 as the New Drug Application to
the US Food and Drug Administration (FDA) and lovastatin,
was approved by FDA to become the first commercial statin
in September 1987.[2]